FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer

Cancer Biology and Therapy

Volumn 16, Issue 7, 2015, Pages 1099-1109

  Peng, Xudong ^a   Luo, Zan ^c   Kang, Qingjie ^a   Deng, Dawei ^a   Wang, Qiang ^a   Peng, Hongxia ^b   Wang, Shan ^a   Wei, Zhengqiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b Department of Ophthalmology   (China)

^c CHONGQING THREE GORGES UNIVERSITY   (China)

Author keywords

Aggressive tumor behavior; Colorectal cancer; Epithelial mesenchymal transition; FOXQ1; TGF 1; Wnt signaling

Indexed keywords

BETA CATENIN; FORKHEAD BOX Q1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FOXQ1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; RNA INTERFERENCE; WNT SIGNALING PATHWAY; CELL LINE; CELL MOTION; COLORECTAL TUMOR; DISEASE COURSE; DRUG EFFECTS; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA1; WNT SIGNALING PATHWAY;

EID: 84940960882     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1047568     Document Type: Article

References (31)

1. Christensen J, Bentz S, Sengstag T, Anderle P. FOXQ1, a novel target of the Wnt pathway and a new marker for activation of Wnt signaling in solid tumors. PLoS One. 2013; 8(3): e60051; PMID: 23555880; http://dx. doi. org/10. 1371/journal. pone. 0060051.
2. Yee YK, Tan VP, Chan P, Hung IF, Pang R, Wong BC. Epidemiology of colorectal cancer in Asia. J Gastroenterol Hepatol. 2009; 24: 1810-6; PMID: 20002940; http://dx. doi. org/10. 1111/j. 1440-1746. 2009. 06138. x.
3. Ellis LM. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol. 2004; 31: 3-9; PMID: 15696024; http://dx. doi. org/10. 1053/j. seminoncol. 2004. 11. 028.
4. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009; 361: 2449-60; PMID: 20018966; http://dx. doi. org/10. 1056/NEJMra0804588.
5. Bertrand FE, Angus CW, Partis WJ, Sigounas G. Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle. 2012; 11: 4344-51; PMID: 23032367; http://dx. doi. org/10. 4161/cc. 22134.
6. Patai AV, Molnar B, Tulassay Z, Sipos F. Serrated pathway: alternative route to colorectal cancer. World J Gastroenterol. 2013; 19: 607-15; PMID: 23431044; http://dx. doi. org/10. 3748/wjg. v19. i5. 607.
7. Sheen YY, Kim MJ, Park SA, Park SY, Nam JS. Targeting the Transforming Growth Factor-beta Signaling in Cancer Therapy. Biomol Ther (Seoul). 2013; 21: 323-31; PMID: 24244818.
8. Bieller A, Pasche B, Frank S, Glaser B, Kunz J, Witt K, Zoll B. Isolation and characterization of the human forkhead gene FOXQ1. DNA Cell Biol. 2001; 20: 555-61; PMID: 11747606; http://dx. doi. org/10. 1089/104454901317094963.
9. Zhang H, Meng F, Liu G, Zhang B, Zhu J, Wu F, Ethier SP, Miller F, Wu G. Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res. 2011; 71: 1292-301; PMID: 21285253; http://dx. doi. org/10. 1158/0008-5472. CAN-10-2825.
10. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT. PLoS One. 2012; 7: e39937; PMID: 22761930; http://dx. doi. org/10. 1371/journal. pone. 0039937.
11. Xia L, Huang W, Tian D, Zhang L, Qi X, Chen Z, Shang X, Nie Y, Wu K. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression. Hepatology. 2014; 59: 958-73; PMID: 24005989; http://dx. doi. org/10. 1002/hep. 26735.
12. Zhu Z, Zhu Z, Pang Z, Xing Y, Wan F, Lan D, Wang H. Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer. Int J Oncol. 2013; 42: 1271-8; PMID: 23403865.
13. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Cancer Res. 2010; 70: 2053-63; PMID: 20145154; http://dx. doi. org/10. 1158/0008-5472. CAN-09-2161.
14. Abba M, Patil N, Rasheed K, Nelson LD, Mudduluru G, Leupold JH, Allgayer H. Unraveling the role of FOXQ1 in colorectal cancer metastasis. Mol Cancer Res. 2013; 11: 1017-28; PMID: 23723077; http://dx. doi. org/10. 1158/1541-7786. MCR-13-0024.
15. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 2006; 25: 7531-7; PMID: 17143297; http://dx. doi. org/10. 1038/sj. onc. 1210059.
16. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-7; PMID: 22810696; http://dx. doi. org/10. 1038/nature11252.
17. Christensen J, Bentz S, Sengstag T, Shastri VP, Anderle P. FOXQ1, a novel target of the Wnt pathway and a new marker for activation of Wnt signaling in solid tumors. PLoS One. 2013; 8: e60051; PMID: 23555880; http://dx. doi. org/10. 1371/journal. pone. 0060051.
18. Feuerborn A, Srivastava PK, Kuffer S, Grandy WA, Sijmonsma TP, Gretz N, Brors B, Grone HJ. The Forkhead factor FoxQ1 influences epithelial differentiation. J Cell Physiol. 2011; 226: 710-9; PMID: 20717954; http://dx. doi. org/10. 1002/jcp. 22385.
19. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology. 2012; 142: 562-71. e2; PMID: 22115830; http://dx. doi. org/10. 1053/j. gastro. 2011. 11. 026.
20. Feuerborn A, Srivastava PK, Kuffer S, GrandyWA, Sijmonsma TP, Gretz N, Brors B, Gröne HJ. The Forkhead factor FoxQ1 influences epithelial differentiation; J. J Cell Physiol. 2011; 226(3): 710-9; PMID: 20717954; http://dx. doi. org/10. 1002/jcp. 22385.
21. Zhu Z, Zhu Z, Pang Z, Xing Y, Wan F, Lan D, Wang H. Short hairpin RNA targeting FOXQ1 inhibits invasion and metastasis via the reversal of epithelial-mesenchymal transition in bladder cancer; J. Int J Oncol. 2013; 42(4): 1271-78; PMID: 23403865.
22. Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007; 82: 114-29; PMID: 17285793; http://dx. doi. org/10. 1016/S0025-6196(11)60974-9.
23. AndreT, Boni C, Mounedji-Boudiaf L, NavarroM, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-51; PMID: 15175436; http://dx. doi. org/10. 1056/NEJMoa032709.
24. Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012; 30: 2624-34; PMID: 22665536; http://dx. doi. org/10. 1200/JCO. 2011. 41. 1140.
25. Cheng YD, Yang H, Chen GQ, Zhang ZC. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther. 2013; 7: 1315-22; PMID: 24204124.
26. Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi SC, Yu Q. FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res. 2011; 71: 3076-86; PMID: 21346143; http://dx. doi. org/10. 1158/0008-5472. CAN-10-2787.
27. Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, Zhao Y, Harris DC, Zheng G. E-cadherin/beta-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011; 2011: 567305; PMID: 22007144.
28. Zhang H, Meng F, Liu G, Zhang B. Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res. 2011; 71(4): 1292-301; PMID: 21285253; http://dx. doi. org/10. 1158/0008-5472. CAN-10-2825.
29. Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi SC, Yu Q. FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res. 2011; 71(8): 3076-86; PMID: 21346143; http://dx. doi. org/10. 1158/0008-5472. CAN-10-2787.
30. Jian H, Shen X, Liu I, Semenov M, He X, Wang XF. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev. 2006; 20: 666-74; PMID: 16543220; http://dx. doi. org/10. 1101/gad. 1388806.
31. Zhou S. TGF-beta regulates beta-catenin signaling and osteoblast differentiation in human mesenchymal stem cells. J Cell Biochem. 2011; 112: 1651-60; PMID: 21344492; http://dx. doi. org/10. 1002/jcb. 23079.